Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014)
Neurogene (NGNE) reported Preferred Dividend Payments of $1.0 for Q2 2014, down 100.0% on a YoY basis from $42130.0 in Q2 2013, and down 99.99% quarter-over-quarter from $19550.0 in Q1 2014.
Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014) Analysis & Trends
Neurogene has reported Preferred Dividend Payments for 2 years, with the latest figure at $1.0 in Q2 2014.
- For the quarter ending Q2 2014, Preferred Dividend Payments fell 100.0% year-over-year to $1.0; the trailing twelve-month figure through Jun 2014 stood at $105988.0 (changed N/A YoY), and the FY2013 full-year result was $123074.0, down 27.05% from the prior year.
- Preferred Dividend Payments for Q2 2014 stood at $1.0, down from $19550.0 in the prior quarter.
- The five-year high for Preferred Dividend Payments was $44307.0 in Q1 2013, with the low at $1.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 1.00 |
| Mar 31, 2014 | 19,550.00 |
| Jun 30, 2013 | 42,130.00 |
| Mar 31, 2013 | 44,307.00 |